bioRxivPharmacology & ToxicologyPreprint
In vitro effect of a non-immunosuppressive FKBP ligand, FK1706, on SARS-CoV-2 replication in combination with antivirals
Abstract
FKBP, a naturally occurring ubiquitous intracellular protein, has been proposed as a potential target for coronavirus replication. A non-immunosuppressive FKBP ligand, FK1706, was studied in vitro in a Vero cell model to assess potential activity alone and in combination with antivirals against SARS-CoV-2 replication. When combined with remdesivir, synergistic activity was seen (summary synergy score 24.7+9.56). FK1706 warrants in vivo testing as a potential new combination therapeutic for the treatment of COVID-19 infections.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An Oral Combination therapy against SARS-CoV-2 based on Synergistic Action of Auranofin and Remdesivir.
Oyahida Khatun, Rohan Narayan, … Shashank Tripathi·bioRxiv·Dec 19, 2025
- Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
L. Jeffreys, S. H. Pennington, … G. A. Biagini·bioRxiv·Dec 23, 2020
- Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir
H. S. Lo, K. P. Y. Hui, … W.-L. Ng·ACS Central SciencePeer-reviewed·Apr 15, 2021
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication
I. L. Shytaj, M. Fares, … M. Lusic·bioRxiv·Mar 9, 2021
- Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
X. Nguyenla, E. Wehri, … J. Schaletzky·bioRxiv·Sep 18, 2020
- Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.
N. E. Stone, S. A. Jaramillo, … C. T. French·bioRxiv·Nov 12, 2020